Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1

Status

Not yet recruiting 2Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Breast 1

Conditions

Breast Neoplasms 576Carcinoma, Non-Small-Cell Lung 490Ovarian Neoplasms 328Lung Neoplasms 208Fallopian Tube Neoplasms 153Neoplasms 152Stomach Neoplasms 128Esophageal Neoplasms 127Triple Negative Breast Neoplasms 125Neoplasm Metastasis 120Carcinoma, Ovarian Epithelial 115Squamous Cell Carcinoma of Head and Neck 96Endometrial Neoplasms 95Uterine Cervical Neoplasms 80Head and Neck Neoplasms 78Esophageal Squamous Cell Carcinoma 76Adenocarcinoma of Lung 49Recurrence 48Parkinson Disease 4, Autosomal Dominant Lewy Body 45Melanoma 42Carcinoma 42Urinary Bladder Neoplasms 41Adenocarcinoma Of Esophagus 36Small Cell Lung Carcinoma 34Carcinoma, Squamous Cell 34Prostatic Neoplasms 32Pancreatic Neoplasms 30Breast Neoplasms, Male 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma, Bronchiolo-Alveolar 26

Interventions

Pemetrexed 14Carboplatin 13osimertinib 11Drug Therapy 9aflutinib 8Gefitinib 8Radiotherapy 6Docetaxel 6Cisplatin 6pembrolizumab 5anlotinib 5Radiosurgery 5Paclitaxel 5icotinib 4Vinorelbine 4Gemcitabine 4Erlotinib Hydrochloride 4tislelizumab 3camrelizumab 3apatinib 3HM781-36B 3toripalimab 2spartalizumab 2rezivertinib 2dacomitinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
NSCLC × Paclitaxel × Clear all
NCT06576635 2026-01-20

LUNG-05

University of Illinois at Chicago

Phase NA Recruiting
29 enrolled
Thoracic

NSCLC

NCT06944470 2025-04-25

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Not yet recruiting
76 enrolled
Thoracic

NSCLC

NCT06746870 2024-12-24

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 2 Not yet recruiting
148 enrolled
BreastThoracic

NSCLC

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated
8 enrolled 7 charts
Thoracic

NSCLC

NCT00874848 2016-11-29

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

HiberCell, Inc.

Phase 2 Completed
90 enrolled 20 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡